In a paradigm-shifting revelation for muscle physiology, researchers have discovered that skeletal muscle growth is not a singular biological process regulated solely by the famous nutrient-sensing pathway, mTORC1. Instead, muscle growth splits into two distinct, mechanically driven avenues: Radial Growth (getting bulkier/thicker), which requires mTORC1, and Longitudinal Growth (getting longer/adding functional units in-series), which is completely mTORC1-independent.
This study challenges the dogma that the longevity drug rapamycin (an mTOR inhibitor) universally blunts muscle adaptation. While rapamycin effectively blocked the thickening of muscle fibers in mice, it failed to stop them from lengthening or adding new sarcomeres. The implications are significant for biohackers balancing longevity protocols with performance: you may be able to improve muscle function and architecture (length) even while inhibiting the “bulking” pathway for lifespan extension during the immediate period after dosing rapamycin. The take home message is that you can exercise during your rapamycin protocol and still get many of the benefits even when blood/sirolimus levels are at their highest.
Impact Evaluation: The impact score of this journal is ~12.5 (IF) / 19.6 (CiteScore), evaluated against a typical high-end range of 0–60+ for top general science. Therefore, this is a High impact journal.
Survival Data: This study was a short-term mechanistic investigation (16-day duration) and did not evaluate lifespan.
Mechanistic Deep Dive
This paper dissects the architecture of hypertrophy into two vector-specific pathways.
1. Radial Growth (Cross-Sectional Area)
Pathway: Canonical mTORC1 signaling.
Mechanism: When mTORC1 is active, it suppresses protein degradation (autophagy/ubiquitin-proteasome). The authors hypothesize that rapamycin blocks radial growth not by stopping synthesis, but by disinhibitingdegradation, causing the muscle to eat its own width gains.
Outcome: Rapamycin abolishes this growth. If you are on high-dose rapamycin, “bulking” (increasing fiber diameter) is mechanically inhibited.
Process: New sarcomeres are inserted into the middle of the fiber, not just the ends.
Visualization: “Hotspots” of newly synthesized proteins (NSPs) appear at regions of Z-line “disarray” or splitting.
Model: Supports the “Yu et al.” model where a Z-line splits, pulling apart to create space for a new sarcomere.
Outcome: Mechanical tension (stretch/load) forces the muscle to lengthen and add contractile units regardless of mTOR status.
Novelty
Pathway Dissociation: This is the first definitive proof that radial and longitudinal growth are governed by separable signaling events.
Visualization of Genesis: Using BONCAT (Biorthogonal Noncanonical Amino Acid Tagging), the authors visually captured the “birth” of new sarcomeres in vivo, identifying “transverse Z-line splitting” as the primary mechanism of elongation.
Critical Limitations
Model Extremity: The “Mechanical Overload” (MOV) model—surgically removing a synergistic muscle—is a catastrophic stressor, far exceeding the stimulus of standard resistance training. The rate of growth (doubling mass in days) is supra-physiological compared to human training.
Inferred Dynamics: The evidence for Z-line splitting is based on static “snapshots” of protein hotspots, not real-time live imaging of sarcomere formation.
Missing Pathway: While they proved what doesn’t drive longitudinal growth (mTOR), they failed to identify what does. The specific mechanosensors (e.g., mechanosensitive ion channels, focal adhesion kinases) driving this rapamycin-proof growth remain unknown.
[Confidence Score: High]
Reasoning: The experimental design uses robust genetic tagging (MetRS mice) and high-resolution imaging. The statistical separation between radial (blocked by rapamycin) and longitudinal (unaffected) effects is stark and reproducible across multiple assays.
What this means for you
If you are using rapamycin for longevity but fear muscle wasting (sarcopenia), this study offers a “loophole.” While rapamycin may blunt your ability to build maximal mass (cross-sectional bulk) for a period immediately after dosing (and some time afterward), it does not appear to stop the muscle from adapting to tension by adding functional units (sarcomeres) and lengthening. Training modalities emphasizing loaded stretching (eccentric loading at long muscle lengths) might bypass the mTOR blockade to maintain muscle quality and function.
The Strategic FAQ
1. Is “longitudinal growth” just a euphemism for stretch-induced injury and edema?
Answer: Unlikely. While edema is common in overload models, the study explicitly quantified serial sarcomere number (structural addition) and normalized for fiber length. The observation of “NSP hotspots” (new protein synthesis) specifically at Z-line splits suggests active remodeling, not just swelling. However, Z-line “disarray” is historically a marker of damage, so the line between “micro-injury” and “growth mechanism” is thin.
2. The mouse dose (8.5 mg/day Human Equivalent Dose) is massive. Does a standard longevity pulse (6 mg/week) even block radial hypertrophy?
Answer: Probably not completely. Human studies show that acute resistance exercise activates mTORC1 signaling for 24-48 hours. A weekly pulse of Rapamycin might blunt the signal for 1-2 days, but the remaining “mTOR-free” days could allow for compensatory radial growth. The study proves that even if you block it 100%, longitudinal growth persists.
3. Does this “Z-line splitting” mechanism apply to slow-twitch (Type I) fibers?
Answer: The study focused on the plantaris, which is predominantly fast-twitch (Type II) in mice. Slow-twitch fibers (soleus) often rely more on oxidative metabolism and have different dystrophin/titin complexes. We cannot assume this mechanism translates perfectly to postural muscles without further data.
4. If I am on Rapamycin, what specific exercises should I do to exploit this “Rapamycin-insensitive” pathway?
Answer: You need Long Muscle Length Training. The mouse model involved “chronic dorsiflexion” (stretch). In humans, this translates to exercises like Romanian Deadlifts, Overhead Triceps Extensions, or Seated Leg Curlswhere peak tension occurs while the muscle is fully stretched. Isometric holds at long lengths may also be effective.
5. Does this growth translate to strength (force production) or just length?
Answer: Longitudinal growth increases contraction velocity and the range of motion over which force can be produced, but it adds less peak contractile force than radial growth (adding parallel sarcomeres). It builds a “faster” and more resilient muscle, not necessarily a “stronger” one in static terms.
6. Why did Rapamycin block radial growth but not protein synthesis accumulation?
Answer: This is the study’s paradox. Rapamycin blocked the width increase but didn’t stop the overall accumulation of new proteins. The authors hypothesize that mTORC1 suppression disinhibited autophagy (protein breakdown), so the muscle was synthesizing protein but “eating” the radial gains, while the longitudinal structure remained protected or was energetically prioritized.
The payoff for increasing longitudinal fiber length seems like it’s worth it:
8 weeks of MOV led to a 13% increase in the length of the fibers in the mouse plantaris muscle, and when we applied a geometric model to predict the impact that this would have on whole muscle CSA, we found that this modest increase in fiber length should lead to a 52% increase in mid-belly CSA
Increase in Mid belly csa is basically how muscles grows through the mtor sensitive path.
changes in whole muscle cross-sectional area (CSA) are often used as a proxy for muscle mass, and the two are often viewed as interchangeable in the literature
This puts the old discussion about whether to lift on Rapamycin days or to rest. I try to train any muscle group on 48 hrs rest. I try to train daily, but I almost always train at least 3 days a week. This study suggests that all of these training sessions are beneficial whether they occur on Rapamycin days or not. I have noticed that the strength and muscle mass gains tend to be max at about 9 days after a Rapa dose.
We already knew that muscle mass gains were blunted (not completely negated ) when m-TOR was low. This paper explains the mechanism, and a training modality that that doesn’t seem to depend on m-TOR for some muscle gains.
The study was done in rodents, but there is human literature on sarcomerogenesis, which is the technical term for longitudinal muscle growth. The mechanism of sarcomerogenesis is the same in both species.
Also, note that this is a good strategy for any intervention that drives down m-TOR : fasting, rapamycin usage, weight loss, GLP1 usage, etc
